FDA Prescribing Information, WEGOVY (semaglutide) Boxed Warning: Risk of Thyroid C-Cell Tumors (medullary thyroid carcinoma)
Tirzepatide is administered as a once-weekly subcutaneous injection, with dosing typically initiated at 2.5 mg and gradually titrated upward (5 mg, 7.5 mg, 10 mg, 12.5 mg, to a maximum of 15 mg) based on glycemic response and tolerability
Some studies suggest that injecting into the abdomen might be less painful compared to the other sites
The recommended dose is 5 mcg twice daily initially, which may be increased to 10 mcg twice daily after one month based on clinical response and tolerability
This hormone improves how your body processes nutrients and enhances insulin secretion when blood sugar rises
Providers market these combinations as offering additional benefits beyond weight management, though the evidence base for sublingual delivery of these combinations is similarly limited